Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
The main questions it aims to answer are:
* Safety and tolerability of the novel stem cell formulation
* Potential efficacy of the novel stem cell formulation
Participants will receive a single subretinal injection in their study eye and followed up for safety.
This is an India only study and the product is developed indigenously.
A Phase 1/2a Multi-Center Dose-Escalation Dose-Expansion Study toEvaluate the Safety and Efficacy of Eyecyte-RPE™ when administered as aSingle-dose Subretinal Injection in Subjects with Geographic AtrophyGA Secondary to Dry Age-related Macular Degeneration d-AMD - NIL
100 Clinical Results associated with Eyestem Research Pvt Ltd.
0 Patents (Medical) associated with Eyestem Research Pvt Ltd.
100 Deals associated with Eyestem Research Pvt Ltd.
100 Translational Medicine associated with Eyestem Research Pvt Ltd.